Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...
During Q4, ClearBridge International Growth EAFE Strategy underperformed its MSCI EAFE Index benchmark and MSCI EAFE Growth ...
Zacks Investment Research on MSN
Why Merck's 32% rally isn't enough to change the bearish view
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback